ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2101 • ACR Convergence 2022

    Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study

    Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
  • Abstract Number: 2095 • ACR Convergence 2022

    Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry

    Laura Cáceres1, Iñigo Rúa-Figueroa1, Norman Jimenez2, María Galindo-Izquierdo3, Jaime Calvo4, Raul Menor Almagro5, Antonio Fernandez-Nebro6, Julia Martinez-Barrio7, Esther Rodriguez Almaraz3, Esther Uriarte Isacelaya8, Elena Aurrecoechea9, Natalia Mena Vazquez6, José Miguel Senabre10, José Antonio Bernal11, Ana Pérez12, Vicente Torrente13, F. Javier Narváez14, Clara Sangüesa15, Marta Arévalo16, Mercedes Freire17, Clara Moriano18, Carlota Iñiguez19, Eva Tomero Muriel20, José Luis Andreu21, Mª Jesús García22, Tatiana Cobo23, Gema Bonilla24, Nuria Lozano25, Loreto Horcada26, Carlos Montilla27, Lorena Expósito28, María Esther Ruiz29, José Eloy Oller30, Ángela Pecondón31, Javier Loricera32, Francisco Javier Novoa33, Eva Salgado34, Tarek Carlos Salman-Monte35, Alejandro Muñoz36, Jorge J Fragío Gil37 and Jose M Pego-Reigosa38, 1Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 2IRIDIS Group, Vigo, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario de Araba, Vitoria, Spain, 5Hospital Jerez de la Frontera, Cádiz, Spain, 6Regional University Hospital of Málaga, Málaga, Spain, 7Hospital General Universitario Gregorio Marañón, Madrid, Spain, 8Hospital Universitario Donostia, Donostia, Spain, 9Hospital de Sierrallana, Torrelavega, Spain, 10Hospital Marina Baixa, Villajoyosa, Spain, 11Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 12University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 13Hospital de Sant Joan Despí Moisès Broggi/Consorci Sanitari Integral (CSI), Sant Joan Despí, Spain, 14Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 15Hospital Universitario Severo Ochoa, Madrid, Spain, 16Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 17Complejo H. Universitario de A Coruña, A Coruña, Spain, 18Complejo Asistencial Universitario de León, León, Spain, 19Hospital Universitario Lucus Augusti, Division of Rheumatology, Lugo, Spain, 20Hospital Universitario La Princesa, Madrid, Spain, 21Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 22Hospital Universitario Ramón y Cajal, Madrid, Spain, 23Hospital Infanta Sofía, San Sebastián de los Reyes, Spain, 24Hospital Universitario La Paz, Madrid, Spain, 25Hospital Virgen de la Arrixaca, Murcia, Spain, 26Complejo Hospitalario de Navarra, Pamplona, Spain, 27Complejo asistencial Universitario de Salamanca, Salamanca, Spain, 28Hospital Universitario de Canarias, La Laguna, Spain, 29Hospital Universitario de Basurto, Bilbao, Spain, 30Hospital Universitario Dr. Peset, València, Spain, 31Hospital Universitario Miguel Servet, Zaragoza, Spain, 32Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Complejo Hospitalario Universitario Insular de Gran Canarias, Las Palmas de Gran Canaria, Spain, 34Complejo Hospitalario De Orense, Ourense, Spain, 35Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 36Hospital Universitario Virgen del Rocío, Sevilla, Spain, 37Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, 38Hospital Meixoeiro, Vigo, Spain

    Background/Purpose: There is currently no agreement on which scale should be used to evaluate SLE disease activity. The aim of this study was to analyze…
  • Abstract Number: 2099 • ACR Convergence 2022

    Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers

    Ioannis Parodis1, Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2 and Guillermo Barturen2, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
  • Abstract Number: 2100 • ACR Convergence 2022

    Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus

    Lily Lim1, Menelaos Konstanidis2, Zahi Touma3, Diane Lacaille4, Umut Oguzoglu1, Christine Peschken1, Nicole Anderson3, Ramandeep Kaur1 and Eleanor Pullenayegum2, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Young adulthood (18-30 years) is a time of many changes. Young adults finish school, enter the labour force, and maybe start their own families.…
  • Abstract Number: 2094 • ACR Convergence 2022

    Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)

    R. Ezequiel Borgia1, Manuel Ugarte-Gil2, Luis Vilá3, John Reveille4, Gerald McGwin5 and Graciela Alarcón6, 1UH Rainbow Babies & Children's Hospital, Cleveland, OH, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3University of Puerto Rico Medical Sciences Campus, San Juan, PR, 4University of Texas McGovern Medical School, Houston, TX, 5Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, 6The University of Alabama at Birmingham, Oakland

    Background/Purpose: To examine and compare baseline predictors of improvement in HRQoL in adults with systemic lupus erythematosus (SLE) with disease onset occurring before age 24…
  • Abstract Number: 2032 • ACR Convergence 2022

    Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

    Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

    Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
  • Abstract Number: 2041 • ACR Convergence 2022

    Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome

    SABA NAYAR1, Jason D. turner1, Saba Asam1, Charlotte G. Smith1, Serena Colfrancesco2, Ana Teodósio1, Joe Flint1, David H Gardner1, Professor Simon Bowman3, Adam Croft1, Andrew Filer1, Benjamin A. Fisher1, Christopher Buckley4 and Francesca Barone5, 1University of Birmingham, Birmingham, United Kingdom, 2University of Rome, Rome, Italy, 3University Hospitals Birmingham, Birmingham, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5University of Birmingham, Needham, MA

    Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
  • Abstract Number: 2086 • ACR Convergence 2022

    Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

    Ann E Clarke1, Manuel Ugarte-Gil2, Megan Barber3, John Hanly4, Murray Urowitz5, Yvan St. Pierre6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Sasha Bernatsky6, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33, Bernardo Pons-Estel34 and Graciela Alarcón35, 1University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 7Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 10Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 35The University of Alabama at Birmingham, Oakland

    Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
  • Abstract Number: 1968 • ACR Convergence 2022

    Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis

    Klára Prajzlerová1, Olga Kryštůfková2, Nora Petrovská2, Petra Hánová1, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
  • Abstract Number: 1471 • ACR Convergence 2022

    Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients

    Izza Bazigh1, Uzair Khan2, Achint Patel3, Aaparna Singh3, Neha Ghalib3, Ghazi Farman4, Salman Muddassir3, Farrukh Zaidi5, Sami Mughni3 and Adam Grunbaum6, 1HCA Florida Oak Hill Hospital, Spring Hill, FL, 2HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, 3HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, 4Rehman Medical College, Spring Hill, FL, 5HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, 6Gulf Coast Rheumatology, Trinity, FL

    Background/Purpose: Cardiovascular events occur more frequently and with earlier onset in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies have concluded…
  • Abstract Number: 2073 • ACR Convergence 2022

    The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies

    Laurence S Magder1, Andrea Fava2, Daniel W. Goldman3 and Michelle Petri3, 1University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
  • Abstract Number: 2097 • ACR Convergence 2022

    Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis

    David Kellner1, Jonathan Zuckerman1, Jennifer Grossman2 and Maureen McMahon2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Renal biopsy has long been the gold standard for diagnosis of lupus nephritis (LN), and pathologic features on biopsy are commonly used to guide…
  • Abstract Number: 2082 • ACR Convergence 2022

    A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy

    Dario Roccatello1, Savino Sciascia2, Carla Naretto1, Mirella Alpa1, Roberta Fenoglio1, Michela Ferro1, Giacomo Quattrocchio1, Elena Rubini1, Elnaz Rahbani1, Vittorio Modena1 and Daniela Rossi1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
  • Abstract Number: 2050 • ACR Convergence 2022

    Stratification on Baseline Interferon Scores and Use of CRESS to Improve the Design of Future Trials in Sjögren’s Syndrome: Post Hoc Analysis from a Randomized Controlled Trial

    jacques-eric gottenberg1, Bryan Downie2, Oksana Gurtovaya2 and Anubhav Mathur2, 1Strasbourg University Hospital, Strasbourg, France, 2Gilead Sciences, Foster City, CA

    Background/Purpose: A multicenter, global, randomized, Phase 2, double-blind, placebo (PBO)-controlled study showed filgotinib (FIL; 200 mg/d), lanraplenib (LAN; 30 mg/d), and tirabrutinib (TIRA; 40 mg/d)…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • « Previous Page
  • 1
  • …
  • 422
  • 423
  • 424
  • 425
  • 426
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology